Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.

Annals of internal medicine - 20 Mar 2001

Weinstein M C, Goldie S J, Losina E, Cohen C J, Baxter J D, Zhang H, Kimmel A D, Freedberg K A

Abstract excerpt

BACKGROUND: Genotypic sequencing for drug-resistant strains of HIV can guide the choice of antiretroviral therapy. OBJECTIVE: To assess the cost-effectiveness of genotypic resistance testing for patients acquiring drug resistance through failed treatment (secondary resistance) and those infected with resistant virus (primary resistance). DESIGN: Cost-effectiveness analysis with an HIV simulation model...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD4 Lymphocyte Count

Share to Cost-Benefit Analysis

Share to Drug Resistance, Microbial

Share to Life Expectancy

Share to Quality-Adjusted Life Years

Share to Treatment Failure

Source

Identifiers

PMID: 11255519
DOI: 10.7326/0003-4819-134-6-200103200-00008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.PMID 11255519Read ↗

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.Semantic proximity Read ↗

Net benefits of resistance testing directed therapy compared with standard of care in HIV-infected patients with virological failure: A meta-analysis.Semantic proximity Read ↗

Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.Semantic proximity Read ↗

Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income SettingsSemantic proximity Read ↗

The cost of antiretroviral drug resistance in HIV-positive patients.Semantic proximity Read ↗

Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis.Semantic proximity Read ↗

The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach.Semantic proximity Read ↗

Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.Semantic proximity Read ↗

Cost-effectiveness analysis of using antiretroviral drug resistance testing.Semantic proximity Read ↗

Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.Semantic proximity Read ↗

Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.Semantic proximity Read ↗

Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.